肿瘤乏氧是癌症病人预后不良的重要原因。乏氧可能是恶性肿瘤对治疗产生耐受的主要机制,而且乏氧会使肿瘤侵袭性增加。所以检测肿瘤细胞乏氧至关重要,它会为临床上的治疗和肿瘤病人的愈后提供线索。目前检测乏氧方法很多,但是应用于临床上的少之又少。其中核医学(PET/SPECT)分子显像技术在临床上应用最为广泛。乏氧显像剂能够选择性聚集在肿瘤乏氧区域,然后通过核医学(PET/SPECT)进行乏氧的显像。乏氧显像剂分为硝基咪唑类和非硝基咪唑类,临床上和基础实验研究中以前者为主。而_¹⁸F-FMISO是第一代硝基咪唑类乏氧显像剂,目前临床上应用广泛。这篇文章将会对_¹⁸F-FMISO的最新实验及临床研究进展及目前存在的问题等进行综述。

Hypoxia is an important cause of poor prognosis in cancer patients. Hypoxia may be the main mechanism for malignant tumors to develop tolerance to treatment, and hypoxia may increase tumor invasiveness. Therefore, detection of hypoxic tumor cells is very important, which will provide clues for clinical treatment and the recovery of tumor patients. At present, there are many methods to detect hypoxia, but few of them are used in clinic. Nuclear medicine (PET/SPECT) molecular imaging technology is the most widely used in clinical practice. Hypoxic imaging agents can selectively concentrate in tumor hypoxic regions and then perform hypoxic imaging via nuclear medicine (PET/SPECT). Hypoxic imaging agents are divided into nitroimidazoles and non-nitroimidazoles, mainly the former in clinical and basic experimental studies. While 18F-FMISo is the first generation of nitroimidazole hypoxic imaging agent, which is widely used in clinical practice. This article will review the latest experimental and clinical research progress of 18F-FMISo and the existing problems.

国家自然科学(81760528)；